Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The morbidity of colorectal cancer(CRC) is 10%～15% in China.mFolfox6 has become one of the
standard regimes for metastatic colorectal cancer (mCRC). Neutropenia and oxaliplatin-induced
neurotoxicity are the most common adverse effects which even result in discontinue of
chemotherapy, especially for patients suffered from heavily acute neurotoxicity.
Monosialotetrahexosylganglioside is a component of membrane of nerve cells. Previous phase II
clinical trial showed, it can reduce oxaliplatin-induced neurotoxicity(OIN). But it did not
certificated by phase III trial. Investigators designed the phase III trial to investigate
the effect and safety of monosialotetrahexosylganglioside Sodium Injection for prevention OIN
at colorectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital